Five-year cancer survival by stage at diagnosis in Canada.

IF 2.7 2区医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Health Reports Pub Date : 2023-01-18 DOI:10.25318/82-003-x202300100001-eng

Larry F Ellison, Nathalie Saint-Jacques

{"title":"Five-year cancer survival by stage at diagnosis in Canada.","authors":"Larry F Ellison, Nathalie Saint-Jacques","doi":"10.25318/82-003-x202300100001-eng","DOIUrl":null,"url":null,"abstract":"Background: Cancer survival estimates provide insights into the effectiveness of early detection and treatment. The stage of cancer at diagnosis is an important determinant of survival, reflecting the extent and spread at the time of disease detection. This work provides stage-specific, five-year survival results not previously available for Canada.Data and methods: Data reflect the population-based Canadian Cancer Registry death-linked analytic file covering the period from 2010 to 2017. The stage at diagnosis was determined by the Collaborative Stage Data Collection System. Five-year net survival (NS) estimates for Canada excluding Quebec were derived using the Pohar Perme estimator for the five most commonly diagnosed cancers.Results: Except for prostate cancer, NS decreased monotonically with increased stage at diagnosis. For example, female breast cancer NS estimates were 100% (stage I), 92% (stage II), 74% (stage III) and 23% (stage IV). Apart from lung cancer, stage I NS exceeded 90% for all cancers studied. The largest sex-specific difference in NS was for lung cancer stage I (female 66%; male 56%). Stage-specific NS generally decreased with age, particularly for early-stage lung cancer. Between the 2010-to-2012 and 2015-to-2017 periods, NS improved among stage IV prostate, female breast and lung cancer cases, as well as for stage I and III lung cancer cases; however, it did not improve at any stage for colon or rectal cancer cases.Interpretation: The work highlights the importance of detecting cancer early, when treatment is most effective. It demonstrates some progress in stage-specific survival among top cancers in Canada and offers data to inform health policy, including screening, and clinical decisions regarding cancer treatment.","PeriodicalId":49196,"journal":{"name":"Health Reports","volume":"34 1","pages":"3-15"},"PeriodicalIF":2.7000,"publicationDate":"2023-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.25318/82-003-x202300100001-eng","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 4

Abstract

Background: Cancer survival estimates provide insights into the effectiveness of early detection and treatment. The stage of cancer at diagnosis is an important determinant of survival, reflecting the extent and spread at the time of disease detection. This work provides stage-specific, five-year survival results not previously available for Canada.

Data and methods: Data reflect the population-based Canadian Cancer Registry death-linked analytic file covering the period from 2010 to 2017. The stage at diagnosis was determined by the Collaborative Stage Data Collection System. Five-year net survival (NS) estimates for Canada excluding Quebec were derived using the Pohar Perme estimator for the five most commonly diagnosed cancers.

Results: Except for prostate cancer, NS decreased monotonically with increased stage at diagnosis. For example, female breast cancer NS estimates were 100% (stage I), 92% (stage II), 74% (stage III) and 23% (stage IV). Apart from lung cancer, stage I NS exceeded 90% for all cancers studied. The largest sex-specific difference in NS was for lung cancer stage I (female 66%; male 56%). Stage-specific NS generally decreased with age, particularly for early-stage lung cancer. Between the 2010-to-2012 and 2015-to-2017 periods, NS improved among stage IV prostate, female breast and lung cancer cases, as well as for stage I and III lung cancer cases; however, it did not improve at any stage for colon or rectal cancer cases.

Interpretation: The work highlights the importance of detecting cancer early, when treatment is most effective. It demonstrates some progress in stage-specific survival among top cancers in Canada and offers data to inform health policy, including screening, and clinical decisions regarding cancer treatment.

查看原文本刊更多论文

加拿大5年癌症分期生存率。

背景:癌症生存评估为早期发现和治疗的有效性提供了见解。癌症在诊断时的分期是生存的重要决定因素，反映了疾病检测时的程度和扩散。这项工作提供了特定阶段的5年生存结果，这是加拿大以前没有的。数据和方法:数据反映了2010年至2017年期间基于人群的加拿大癌症登记处死亡相关分析文件。诊断阶段由协同阶段数据采集系统确定。加拿大(不包括魁北克)的5年净生存(NS)估计值是使用Pohar Perme估计值对5种最常诊断的癌症得出的。结果:除前列腺癌外，NS随诊断分期增加而单调下降。例如，女性乳腺癌的NS估计分别为100% (I期)、92% (II期)、74% (III期)和23% (IV期)。除肺癌外，所有癌症的I期NS均超过90%。NS的性别差异最大的是肺癌I期(女性66%;男性的56%)。分期特异性NS通常随着年龄的增长而下降，尤其是早期肺癌。在2010- 2012年和2015- 2017年期间，IV期前列腺癌、女性乳腺癌和肺癌患者以及I期和III期肺癌患者的NS有所改善;然而，在结肠或直肠癌病例的任何阶段，它都没有改善。解释:这项工作强调了早期发现癌症的重要性，因为早期治疗最有效。它展示了加拿大主要癌症在特定阶段生存方面取得的一些进展，并为卫生政策提供了数据，包括筛查和有关癌症治疗的临床决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Health Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

7.30

自引率

4.00%

发文量

期刊介绍： Health Reports publishes original research on diverse topics related to understanding and improving the health of populations and the delivery of health care. We publish studies based on analyses of Canadian national/provincial representative surveys or Canadian national/provincial administrative databases, as well as results of international comparative health research. Health Reports encourages the sharing of methodological information among those engaged in the analysis of health surveys or administrative databases. Use of the most current data available is advised for all submissions.